Innoviva, Inc.: stock overview

INVANASDAQHealthcare · Pharmaceutical Preparations

Price

$19.03

November 13, 2026Market cap $1.4B

DCF calculator

What Ploutos Investor adds for Innoviva

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

In short

Innoviva had revenue of $438M over the last 12 months and net income of $193M, a net margin of 44.1%. Revenue grew by 4.1% a year on average over the last 5 years. At $19.03 the shares trade at a P/E of 7.3, against a median of 6.1 over the last 5 fiscal years. It holds more cash than debt, by $323M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$1.4B
74.07M shares
P/E
7.3
Today7.3
Median6.1
Revenue, 12 months
$438M
+4.1% a year over 5 years
Net margin
44.1%
2025: 65.9%, above 99% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+15.1% a year over 2 years

  • 202510-K
    Revenue$411M
  • 202410-K
    Revenue$359M
  • 202310-K
    Revenue$310M

Fiscal years in figures

INVA's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $1.1B
$1.4B
Enterprise value 
$1.1B
P/E 3-year median: 7.3
7.3
EV / EBIT 
6.4
EV / Revenue 
2.5
P/B 3-year median: 1.5
1.2
FCF yield 3-year median: 13.9%
13.0%
Earnings yield 3-year median: 13.7%
13.7%

Profitability

Gross margin 
74.5%
Operating margin 
38.8%
Net margin 3-year median: 57.9%
44.1%
ROIC 
9.5%
ROIC, 5-year average 
17.2%
ROE 
16.4%

Growth

Revenue, yearly change 
+14.7%
EPS, yearly change 
+816.7%
FCF, yearly change 
+3.9%
Revenue, average a year 
+4.1%
EPS, average a year 
+10.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$581M
Total debt 
$270M
Of which operating leases 
$11M
Net cash 
$323M
Net debt / EBITDA 
–
Interest cover 
8.6x
Current ratio 
15.44

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
0.32%
Total returned 
0.32%
Shares, yearly change 
+18.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

74.8%

Above 89% of the 141 companies in its industry, and 91% of all.

Operating margin

39.8%

Above 96% of the 285 companies in its industry, and 96% of all.

Net margin

65.9%

Above 99% of the 302 companies in its industry, and 99% of all.

ROE

23.1%

Above 84% of the 267 companies in its industry, and 87% of all.

ROA

16.6%

Above 89% of the 313 companies in its industry, and 95% of all.

Revenue growth

14.7%

Above 64% of the 292 companies in its industry, and 73% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Innoviva, Inc.
CIK
1080014
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
74.07M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Innoviva's filings show?

These are Innoviva's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about INVA

Didn't find what you were looking for?

Ask us
What is INVA's market cap?

Innoviva, Inc.'s market cap is $1.4B, at a price of $19.03 on November 13, 2026 and 74.07M shares.

What is INVA's P/E?

INVA's P/E is 7.3, on earnings per share of $2.61 over the last 12 months. The median over the last 5 fiscal years was 6.1.

How much revenue does INVA have?

Innoviva had revenue of $438M over the last 12 months. Over the last 5 years it changed by +4.1% a year on average.

Does INVA pay a dividend?

No. Innoviva paid no regular dividend over the last 12 months.

Where do the figures come from?

From Innoviva, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.